07:00 , Aug 3, 2009 |  BC Week In Review  |  Company News

Alexis Biotech, Immunomedics deal

The companies will cross-license their respective drug development technologies to develop vaccines against cancer and infectious diseases, including melanoma, chronic lymphocytic leukemia (CLL) and AIDS. Alexis will have non-exclusive rights to Immunomedics' Dock-and-Lock (DNL) conjugation...
07:00 , May 1, 2006 |  BioCentury  |  Tools & Techniques

Locked and loaded conjugates

An article to be published in this week's Proceedings of the National Academy of Sciences describes a dock and lock (DNL) protein engineering method from Immunomedics Inc. that can be used to create fusion proteins...